CANT1 (Calcium-Activated Nucleotidase 1) antibodies are immunological tools designed to detect and study the CANT1 protein, a member of the apyrase family localized in the endoplasmic reticulum (ER) and Golgi apparatus. These antibodies enable researchers to investigate CANT1’s roles in proteoglycan biosynthesis, glycosylation, and skeletal development, as well as its implications in diseases such as Desbuquois dysplasia type 1 (DBQD1) and cancer .
Role in DBQD1: Knock-out mouse models revealed CANT1’s critical role in glycosaminoglycan (GAG) chain synthesis and sulfation. Loss of CANT1 causes ER enlargement, delayed proteoglycan secretion, and growth plate defects, recapitulating DBQD1 phenotypes .
Mechanism: CANT1 hydrolyzes UDP, a byproduct of glycosyltransferase reactions, to regulate nucleotide levels in the ER/Golgi .
Hepatocellular Carcinoma (HCC): CANT1 overexpression correlates with poor prognosis, advanced tumor stage, and immune cell infiltration (e.g., CD8+ T cells). It serves as an independent prognostic marker (AUC = 0.938) .
Retinoblastoma (RB): LncRNA CANT1 suppresses tumor progression by inhibiting PI3Kγ/Akt signaling. Overexpression reduces tumor growth in vitro and in vivo .
Western Blot: Detected in LNCaP (prostate cancer), U2OS (osteosarcoma), and A549 (lung cancer) cell lines .
Subcellular Localization: Perinuclear staining in PC-3 prostate cancer cells .
| Application | Dilution | Sample Preparation |
|---|---|---|
| Western Blot | 1:500–1:5000 | Reduce lysates with β-mercaptoethanol |
| ICC/IF | 10 µg/mL | Fix cells with paraformaldehyde |